CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
LEV102 1.0% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05715346
NCT05715346Phase 2Completed
CompareCT.gov

A Phase 1/2a Study of LEV102 Topical Gel in Subjects With Acquired Blepharoptosis

Levation Pharma, Ltd.·interventional·Posted Feb 8, 2023·Updated Nov 13, 2024

In Brief

A Phase 2 clinical trial evaluating LEV102 1.0%, LEV102 2.0%, and 1 other intervention for Acquired Blepharoptosis. Completed, enrolled 33 participants across 3 sites.

Detailed Summary

Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcquired Blepharoptosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedFeb 8, 2023
Enrollment StartFeb 23, 2023
Primary CompletionJun 24, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.4 years ago

Interventions

LEV102 1.0%drug

Oxymetazoline ophthalmic gel

LEV102 2.0%drug

Oxymetazoline ophthalmic gel

Vehicledrug

Vehicle ophthalmic gel